Navigation Links
Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/11/2010

DURHAM, N.C., Nov. 11, 2010 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the next steps in the clinical development of Argos' Arcelis™ immunotherapy at the Lazard Capital Markets 7th Annual Healthcare Conference in New York at 11 a.m. EST on Wednesday, Nov. 17, 2010.  The conference will take place at The St. Regis New York.

Argos is in the process of securing funding to begin a Phase 3 trial in renal cell carcinoma (RCC) with its Arcelis immunotherapy, AGS 003, in mid-2011.  The company recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for AGS 003 in combination with sunitinib. Argos' Arcelis HIV program, AGS-004, is also currently being tested in a double-blind, placebo controlled, randomized Phase 2b study co-funded by the NIH to further demonstrate that it is a feasible treatment option of HIV-1 infected patients.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells -- the master switch that turns the immune system on or off. www.argostherapeutics.comContacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
3. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
4. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report Third Quarter 2010 Financial Results on October 28
8. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
9. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
10. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
11. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:8/23/2017)...  The general public,s help is being enlisted in what,s thought to ... and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest ... the gut. The project's goal is to help advance scientific knowledge of ... ...
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
Breaking Biology News(10 mins):